{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:57:19Z","timestamp":1759334239267,"version":"build-2065373602"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873396"],"award-info":[{"award-number":["81873396"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.lungcan.2022.09.006","type":"journal-article","created":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T05:17:33Z","timestamp":1662873453000},"page":"152-153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Suggestions on \u201cPathological complete response to neoadjuvant chemoimmunotherapy correlates with peripheral blood immune cell subsets and metastatic status of mediastinal lymph nodes (N2 lymph nodes) in non-small cell lung cancer\u201d"],"prefix":"10.1016","volume":"175","author":[{"given":"Yixuan","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiabin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zelu","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijuan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2022.09.006_b0005","doi-asserted-by":"crossref","unstructured":"Ma T, Wen T, Cheng X, et al. Pathological complete response to neoadjuvant chemoimmunotherapy correlates with peripheral blood immune cell subsets and metastatic status of mediastinal lymph nodes (N2 lymph nodes) in non-small cell lung cancer [published online ahead of print, 2022 Aug 10]. Lung Cancer 172 (2022) 43-52. 10.1016\/j.lungcan.2022.08.002.","DOI":"10.1016\/j.lungcan.2022.08.002"},{"issue":"8","key":"10.1016\/j.lungcan.2022.09.006_b0010","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/s41571-022-00647-9","article-title":"Role of neoadjuvant chemoimmunotherapy for resectable NSCLC","volume":"19","author":"Sepesi","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.lungcan.2022.09.006_b0015","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.lungcan.2022.09.006_b0020","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.21.00276","article-title":"SAKK 16\/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial","volume":"39","author":"Rothschild","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2022.09.006_b0025","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.athoracsur.2017.09.030","article-title":"Surgical Outcomes After Neoadjuvant Chemotherapy and Ipilimumab for Non-Small Cell Lung Cancer","volume":"105","author":"Yang","year":"2018","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.lungcan.2022.09.006_b0030","unstructured":"Liang W, Cai K, Chen C, et al. Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res. 9(6) 2020 2696-2715. 10.21037\/tlcr-2020-63."},{"issue":"10","key":"10.1016\/j.lungcan.2022.09.006_b0035","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11864-021-00885-6","article-title":"Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer","volume":"22","author":"Gutierrez-Sainz","year":"2021","journal-title":"Curr. Treat. Options Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2022.09.006_b0040","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S1470-2045(20)30140-6","article-title":"Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Shu","year":"2020","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2022.09.006_b0045","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S1470-2045(20)30453-8","article-title":"Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222006201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222006201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:04:30Z","timestamp":1759237470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500222006201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":9,"alternative-id":["S0169500222006201"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.09.006","relation":{},"ISSN":["0169-5002"],"issn-type":[{"type":"print","value":"0169-5002"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suggestions on \u201cPathological complete response to neoadjuvant chemoimmunotherapy correlates with peripheral blood immune cell subsets and metastatic status of mediastinal lymph nodes (N2 lymph nodes) in non-small cell lung cancer\u201d","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}